{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T01:37:23Z","timestamp":1648949843661},"reference-count":18,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1999,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The in vitro activities of 13 fluoroquinolones (FQs) were tested against 90\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            clinical isolates: 30 wild type for\n            <jats:italic>gyrA<\/jats:italic>\n            ,\n            <jats:italic>gyrB<\/jats:italic>\n            ,\n            <jats:italic>grlA<\/jats:italic>\n            and\n            <jats:italic>norA<\/jats:italic>\n            and 60 with mutations in these genes. Clinafloxacin (CI-960), sparfloxacin, and grepafloxacin were the most active FQs against wild-type isolates (MICs at which 90% of isolates were inhibited, 0.06 to 0.1 \u03bcg\/ml). Mutations in\n            <jats:italic>grlA<\/jats:italic>\n            did not affect the MICs of newer FQs.\n            <jats:italic>grlA-gyrA<\/jats:italic>\n            double mutations led to higher MICs for all the FQs tested. Efflux mechanisms affected the newer FQs to a much lesser extent than the less recently developed FQs.\n          <\/jats:p>","DOI":"10.1128\/aac.43.4.966","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:34:41Z","timestamp":1539045281000},"page":"966-968","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["In Vitro Activities of 13 Fluoroquinolones against\n            <i>Staphylococcus aureus<\/i>\n            Isolates with Characterized Mutations in\n            <i>gyrA<\/i>\n            ,\n            <i>gyrB<\/i>\n            ,\n            <i>grlA<\/i>\n            , and\n            <i>norA<\/i>\n            and against Wild-Type Isolates"],"prefix":"10.1128","volume":"43","author":[{"given":"J. L.","family":"Mun\u0303oz Bellido","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Departamento de Microbiolog\u0131\u0301a, Hospital Universitario de Salamanca, Salamanca,1and"}]},{"given":"M. A.","family":"Alonso Manzanares","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Departamento de Microbiolog\u0131\u0301a, Hospital Universitario de Salamanca, Salamanca,1and"}]},{"given":"G.","family":"Yagu\u0308e Guirao","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Departamento de Microbiolog\u0131\u0301a, Hospital General Universitario de Murcia, Murcia,2 Spain"}]},{"given":"M. N.","family":"Gutie\u0301rrez Zufiaurre","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Departamento de Microbiolog\u0131\u0301a, Hospital Universitario de Salamanca, Salamanca,1and"}]},{"given":"M. C. M.","family":"Toldos","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Departamento de Microbiolog\u0131\u0301a, Hospital General Universitario de Murcia, Murcia,2 Spain"}]},{"given":"M.","family":"Segovia Herna\u0301ndez","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Departamento de Microbiolog\u0131\u0301a, Hospital General Universitario de Murcia, Murcia,2 Spain"}]},{"given":"J. A.","family":"Garci\u0301a-Rodri\u0301guez","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Departamento de Microbiolog\u0131\u0301a, Hospital Universitario de Salamanca, Salamanca,1and"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1994.tb00458.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1554"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.121"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.4.879"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1111\/j.1469-0691.1998.tb00684.x","article-title":"Structure of grepafloxacin relative to activity and safety profile.","volume":"4","author":"Hooper D. C.","year":"1998","unstructured":"Hooper D. C. Structure of grepafloxacin relative to activity and safety profile. Clin. Microbiol. Infect. 4 (Suppl. 1) 1998 S15 S20","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2014"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1086"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11801"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1469-0691.1998.tb00683.x","article-title":"Grepafloxacin: microbiological properties.","volume":"4","author":"Marriott M. S.","year":"1998","unstructured":"Marriott M. S. Grepafloxacin: microbiological properties. Clin. Microbiol. Infect. 4 (Suppl. 1) 1998 S9 S14","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1306"},{"key":"e_1_3_2_12_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Approved standard M7-A3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\n          3rd ed.\n          1993\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.471"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5463"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jac\/41.4.481","article-title":"Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY-12-8039) MICs and mutations in grlA,grlB,gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.","volume":"41","author":"Schmitz F. J.","year":"1998","unstructured":"Schmitz F. J. Hofmann B. Hansen B. Scheuring S. Lackefahr M. Klootwijk M. Verhoef J. Fluit A. Heinz H. P. Kohrer K. Jones M. E. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY-12-8039) MICs and mutations in grlA,grlB,gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41 1998 481 484","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.172.12.7260-7262.1990"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1073\/pnas.74.11.4767","article-title":"Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.","volume":"74","author":"Sugino A.","year":"1977","unstructured":"Sugino A. Peebles C. L. Kreuzer K. N. Cozzarelli N. R. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl. Acad. Sci. USA 74 1977 4767 4771","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1835"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.491"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.4.966","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.4.966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:58:32Z","timestamp":1645459112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.43.4.966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["10.1128\/AAC.43.4.966"],"URL":"http:\/\/dx.doi.org\/10.1128\/aac.43.4.966","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,4]]},"assertion":[{"value":"1998-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}